GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Institutional Ownership

Xbrane Biopharma AB (STU:7XB) Institutional Ownership : 3.36% (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xbrane Biopharma AB's institutional ownership is 3.36%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xbrane Biopharma AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xbrane Biopharma AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Xbrane Biopharma AB Institutional Ownership Historical Data

The historical data trend for Xbrane Biopharma AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Institutional Ownership Chart

Xbrane Biopharma AB Historical Data

The historical data trend for Xbrane Biopharma AB can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 1.64 1.52 1.19 0.88 0.81 0.75 0.54 0.41 2.64 3.36

Xbrane Biopharma AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Xbrane Biopharma AB (STU:7XB) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines